| scholarly article | Q13442814 |
| P50 | author | Soňa Nevšímalová | Q12055524 |
| Christelle Peyron | Q34639616 | ||
| P2093 | author name string | R Kucherlapati | |
| R Li | |||
| J Fan | |||
| E Mignot | |||
| R Maki | |||
| S Nishino | |||
| W Rogers | |||
| Y Charnay | |||
| J Faraco | |||
| G J Lammers | |||
| S Overeem | |||
| D Reynolds | |||
| M Pedrazzoli | |||
| C Bouras | |||
| R Albin | |||
| M Aldrich | |||
| B Ripley | |||
| M Hungs | |||
| M Kucherlapati | |||
| M Padigaru | |||
| P2860 | cites work | Three novel proteins of the syntaxin/SNAP-25 family | Q22008531 |
| Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior | Q24315738 | ||
| The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity | Q24317782 | ||
| The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene | Q28142783 | ||
| Structure and function of human prepro-orexin gene | Q28611050 | ||
| Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation | Q29615680 | ||
| Neurons containing hypocretin (orexin) project to multiple neuronal systems | Q29619641 | ||
| Orexin A activates locus coeruleus cell firing and increases arousal in the rat. | Q30504135 | ||
| The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease | Q33782327 | ||
| The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. | Q33910875 | ||
| Autoimmune hypothesis in narcolepsy | Q34361380 | ||
| DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. | Q34721708 | ||
| Pharmacological aspects of human and canine narcolepsy | Q34740875 | ||
| Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum | Q39782823 | ||
| Genetic and familial aspects of narcolepsy | Q41713413 | ||
| Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. | Q45972137 | ||
| Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model | Q46582738 | ||
| Characterization of orexin-A and orexin-B in the microdissected rat brain nuclei and their contents in two obese rat models | Q48101411 | ||
| Distribution and quantification of immunoreactive orexin A in rat tissues. | Q48112935 | ||
| Perspectives in narcolepsy and hypocretin (orexin) research | Q48724319 | ||
| Clinical and polysomnographic features in DQB1*0602 positive and negative narcolepsy patients: results from the modafinil clinical trial | Q48726831 | ||
| Hypocretin (orexin) deficiency in human narcolepsy. | Q55033530 | ||
| Narcolepsy and immunity | Q60399980 | ||
| Narcolepsy | Q68526268 | ||
| HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive | Q70974817 | ||
| Inefficient membrane targeting, translocation, and proteolytic processing by signal peptidase of a mutant preproparathyroid hormone protein | Q72428569 | ||
| Mapping of cocaine and amphetamine regulated transcript (CART) mRNA expression in the hypothalamus of elderly human | Q73299653 | ||
| Narcolepsy in prepubertal children | Q74122093 | ||
| Dynamics of microglial activation in the spinal cord after cerebral infarction are revealed by expression of MHC class II antigen | Q77147999 | ||
| Mutations in the vasopressin prohormone involved in diabetes insipidus impair endoplasmic reticulum export but not sorting | Q78010486 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| narcolepsy | Q189561 | ||
| P304 | page(s) | 991-7 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains | |
| P478 | volume | 6 |
| Q36493198 | "No thanks, it keeps me awake": the genetics of coffee-attributed sleep disturbance |
| Q46514264 | A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? |
| Q27016617 | A Framework for Quantitative Modeling of Neural Circuits Involved in Sleep-to-Wake Transition |
| Q44147997 | A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid |
| Q37148480 | A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y |
| Q37384459 | A consensus definition of cataplexy in mouse models of narcolepsy. |
| Q35204907 | A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy |
| Q21262952 | A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep |
| Q38103817 | A unified survival theory of the functioning of the hypocretinergic system |
| Q34369364 | A unifying computational framework for stability and flexibility of arousal |
| Q91860704 | A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia |
| Q33740907 | A1 receptor mediated adenosinergic regulation of perifornical-lateral hypothalamic area neurons in freely behaving rats |
| Q41506763 | Aberrant Food Choices after Satiation in Human Orexin-Deficient Narcolepsy Type 1 |
| Q34216671 | Abnormal sleep-cardiovascular system interaction in narcolepsy with cataplexy: effects of hypocretin deficiency in humans |
| Q24618853 | Abnormally low serum acylcarnitine levels in narcolepsy patients |
| Q37315558 | Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy |
| Q43063705 | Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways |
| Q37590372 | Activation of the basal forebrain by the orexin/hypocretin neurones. |
| Q35745240 | Activity Suppression Behavior Phenotype in SULT4A1 Frameshift Mutant Zebrafish |
| Q24678224 | Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs |
| Q37113726 | Activity of pontine neurons during sleep and cataplexy in hypocretin knock-out mice |
| Q37395932 | Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. |
| Q37080576 | Addiction and arousal: the hypocretin connection. |
| Q36485245 | Afferents to the orexin neurons of the rat brain |
| Q46458892 | Age-related changes in hypocretin (orexin) immunoreactivity in the cat brainstem |
| Q48460329 | Age-related decline in hypocretin (orexin) receptor 2 messenger RNA levels in the mouse brain. |
| Q92988501 | Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework |
| Q36608029 | Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy |
| Q35884309 | Altered Sleep Stage Transitions of REM Sleep: A Novel and Stable Biomarker of Narcolepsy |
| Q48181755 | Altered circadian rhythm of melatonin concentrations in hypocretin-deficient men. |
| Q36992047 | Amygdala lesions reduce cataplexy in orexin knock-out mice. |
| Q42930740 | An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture |
| Q28289535 | An approach based on a genome-wide association study reveals candidate loci for narcolepsy |
| Q46217420 | An autoantibody in narcolepsy disrupts colonic migrating motor complexes. |
| Q36497164 | An emerging link between general anesthesia and sleep |
| Q36764549 | Animal models of narcolepsy |
| Q36531042 | Antagonism of orexin receptors in the posterior hypothalamus reduces hypoglossal and cardiorespiratory excitation from the perifornical hypothalamus |
| Q33950168 | Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy |
| Q33950173 | Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy |
| Q30376254 | Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. |
| Q24804299 | ApoE polymorphisms in narcolepsy |
| Q92878428 | Arousal and sleep circuits |
| Q33934848 | Arousal effect of orexin A depends on activation of the histaminergic system |
| Q48614032 | Article reviewed: Plasma orexin-A is lower in patients with narcolepsy |
| Q33360439 | Association of narcolepsy-cataplexy with HLA-DRB1 and DQB1 in Mexican patients: a relationship between HLA and gender is suggested |
| Q39229203 | Attacking sleep from a new angle: contributions from zebrafish |
| Q36473267 | Attenuated heart rate response is associated with hypocretin deficiency in patients with narcolepsy. |
| Q33875477 | Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency. |
| Q46172090 | Autoimmunity in narcolepsy |
| Q60959234 | Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy |
| Q34500458 | Autonomic response to periodic leg movements during sleep in narcolepsy-cataplexy |
| Q39135562 | Basal Forebrain Cholinergic System and Orexin Neurons: Effects on Attention |
| Q48441167 | Behavioral and sleep/wake characteristics of mice lacking norepinephrine and hypocretin |
| Q34836843 | Benefits and risks of pharmacotherapy for narcolepsy. |
| Q35002650 | Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor |
| Q38686031 | Biology of Neuropeptides: Orexinergic Involvement in Primary Headache Disorders |
| Q37402576 | Body mass index-independent metabolic alterations in narcolepsy with cataplexy. |
| Q36258096 | Brain regulation of food intake and appetite: molecules and networks |
| Q42248160 | CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy |
| Q30818202 | CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. |
| Q33783832 | CSF biomarkers in suicide attempters--a principal component analysis. |
| Q37083146 | CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome |
| Q48618238 | CSF hypocretin levels in Guillain–Barré syndrome and other inflammatory neuropathies |
| Q34593339 | CSF hypocretin-1 assessment in sleep and neurological disorders |
| Q35560285 | CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions |
| Q48607617 | CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture |
| Q34196054 | Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. |
| Q24643046 | Canine behavioral genetics: pointing out the phenotypes and herding up the genes |
| Q48180728 | Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal |
| Q46519577 | Cardiovascular variability as a function of sleep-wake behaviour in narcolepsy with cataplexy |
| Q35496832 | Carnivore-specific SINEs (Can-SINEs): distribution, evolution, and genomic impact |
| Q47867265 | Cataplexy--clinical aspects, pathophysiology and management strategy. |
| Q44905905 | Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior |
| Q42521954 | Cataplexy-related neurons in the amygdala of the narcoleptic dog. |
| Q35573160 | Cataplexy: 'tonic immobility' rather than 'REM-sleep atonia'? |
| Q37502513 | Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders |
| Q38072632 | Central functions of the orexinergic system |
| Q42664046 | Centrally administered orexin A increases motivation for sweet pellets in rats |
| Q36503678 | Cerebrospinal fluid hypocretin (orexin) levels are elevated by play but are not raised by exercise and its associated heart rate, blood pressure, respiration or body temperature changes |
| Q33587560 | Challenges in diagnosing narcolepsy without cataplexy: a consensus statement |
| Q38684472 | Challenges in the development of therapeutics for narcolepsy |
| Q38944800 | Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders |
| Q60034744 | Chapter 26 Excessive daytime sleepiness |
| Q37628048 | Chapter 34: the history of sleep medicine |
| Q28083212 | Characterization of a mammalian prosencephalic functional plan |
| Q21145872 | Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants |
| Q34566307 | Childhood sleep disorders: diagnostic and therapeutic approaches. |
| Q34441989 | Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. |
| Q27347659 | Cholinergic modulation of narcoleptic attacks in double orexin receptor knockout mice |
| Q26766524 | Chronic sleep disturbance and neural injury: links to neurodegenerative disease |
| Q44419027 | Circadian and Homeostatic Regulation of Hypocretin in a Primate Model: Implications for the Consolidation of Wakefulness |
| Q35015762 | Circadian rhythms, sleep, and metabolism |
| Q57169318 | Circuit mechanisms and computational models of REM sleep |
| Q35995182 | Clinical and neurobiological aspects of narcolepsy |
| Q34197619 | Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children |
| Q34272523 | Clinical aspects and pathophysiology of narcolepsy |
| Q37409612 | Cluster headache, hypothalamus, and orexin. |
| Q38005441 | Co-morbidity of complex genetic disorders and hypersomnias of central origin: lessons from the underlying neurobiology of wake and sleep. |
| Q51928470 | Coexistence of TACS and trigeminal neuralgia: pathophysiological conjectures. |
| Q48492945 | Cognitive deficits in narcolepsy |
| Q50937047 | Comment on "Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2". |
| Q47946117 | Commentary: A Quest for a Novel Peripheral Biomarker for Narcolepsy. |
| Q34482367 | Common variants in P2RY11 are associated with narcolepsy |
| Q36831252 | Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study |
| Q34113276 | Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups |
| Q35606698 | Complex movement disorders at disease onset in childhood narcolepsy with cataplexy |
| Q36477752 | Concomitant loss of dynorphin, NARP, and orexin in narcolepsy |
| Q40059782 | Connexin 43-Mediated Astroglial Metabolic Networks Contribute to the Regulation of the Sleep-Wake Cycle. |
| Q64904970 | Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. |
| Q24634619 | Control of sleep and wakefulness |
| Q36079899 | Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice |
| Q27027931 | Controlling complexity: the clinical relevance of mouse complex genetics |
| Q33619265 | Coreleased orexin and glutamate evoke nonredundant spike outputs and computations in histamine neurons |
| Q47577824 | Correlates to Problem Behaviors in Pediatric Narcolepsy: A Pilot Study |
| Q33490294 | Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes). |
| Q27643106 | Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy |
| Q43184131 | DNA methyltransferase 1 mutations and mitochondrial pathology: is mtDNA methylated? |
| Q37397544 | DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe |
| Q36408225 | DQB1*06:02 allele-specific expression varies by allelic dosage, not narcolepsy status |
| Q34405585 | Decision making in narcolepsy with cataplexy |
| Q37083142 | Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. |
| Q43780972 | Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs |
| Q39231424 | Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder |
| Q30477079 | Delayed arousal |
| Q55982676 | Delineation of Late Onset Hypoventilation Associated with Hypothalamic Dysfunction Syndrome |
| Q48032095 | Demonstration of an orexinergic central innervation of the pineal gland of the pig. |
| Q42503281 | Descending projections from the basal forebrain to the orexin neurons in mice. |
| Q39837708 | Desynchronization of the Rat Cortical Network and Excitation of White Matter Neurons by Neurotensin. |
| Q36709071 | Detection of orexin A neuropeptide in biological fluids using a zinc oxide field effect transistor |
| Q48313244 | Development of the zebrafish hypothalamus. |
| Q46620941 | Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers |
| Q37077941 | Developmental divergence of sleep-wake patterns in orexin knockout and wild-type mice |
| Q34997848 | Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations |
| Q35700616 | Different neuronal phenotypes in the lateral hypothalamus and their role in sleep and wakefulness |
| Q37406178 | Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy. |
| Q34500176 | Differential diagnosis in hypersomnia |
| Q48623508 | Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats |
| Q41818726 | Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep |
| Q38111376 | Differential roles of orexin receptors in the regulation of sleep/wakefulness. |
| Q48338808 | Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. |
| Q34121230 | Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsy |
| Q46549069 | Direct excitation of hypocretin/orexin cells by extracellular ATP at P2X receptors |
| Q46598680 | Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. |
| Q37522859 | Discovery and development of orexin receptor antagonists as therapeutics for insomnia |
| Q47839193 | Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach |
| Q50186689 | Discovery of Hypocretin/Orexin Ushers in a New Era of Sleep Research |
| Q35425908 | Disease and Degeneration of Aging Neural Systems that Integrate Sleep Drive and Circadian Oscillations |
| Q36808752 | Disrupted Sleep in Narcolepsy: Exploring the Integrity of Galanin Neurons in the Ventrolateral Preoptic Area |
| Q83232822 | Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice |
| Q42825760 | Distinct effects of IPSU and suvorexant on mouse sleep architecture |
| Q44472346 | Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes |
| Q47775194 | Distribution of HLA-DQB1 in Czech Patients with Central Hypersomnias. |
| Q48693131 | Distribution of hypocretin-(orexin) immunoreactivity in the central nervous system of Syrian hamsters (Mesocricetus auratus). |
| Q33751843 | Diurnal fluctuation in the number of hypocretin/orexin and histamine producing: Implication for understanding and treating neuronal loss |
| Q44520873 | Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects |
| Q43089620 | Do enteric neurons make hypocretin? |
| Q33573841 | Does narcolepsy symptom severity vary according to HLA-DQB1*0602 allele status? |
| Q42128141 | Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. |
| Q32062046 | Dopaminergic role in stimulant-induced wakefulness. |
| Q36956971 | Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels |
| Q92110230 | Dual orexin and MCH neuron-ablated mice display severe sleep attacks and cataplexy |
| Q38108972 | Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders |
| Q47657713 | Dual-transmitter systems regulating arousal, attention, learning and memory. |
| Q24311664 | ELABELA: a hormone essential for heart development signals via the apelin receptor |
| Q36493247 | Eating disorder and metabolism in narcoleptic patients |
| Q34442715 | Effects of ambient temperature on sleep and cardiovascular regulation in mice: the role of hypocretin/orexin neurons |
| Q42509494 | Effects of hypocretin-saporin injections into the medial septum on sleep and hippocampal theta |
| Q35149403 | Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats |
| Q33947731 | Effects of hypocretin2-saporin and antidopamine-beta-hydroxylase-saporin neurotoxic lesions of the dorsolateral pons on sleep and muscle tone |
| Q48405838 | Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2-saporin on sleep in Long-Evans rats |
| Q21133761 | Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial |
| Q36473239 | Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice |
| Q40752526 | Effects of orexin on cultured porcine adrenal medullary and cortex cells |
| Q34287174 | Effects of saporin-induced lesions of three arousal populations on daily levels of sleep and wake |
| Q42329929 | Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins |
| Q48693700 | Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. |
| Q44932733 | Electroencephalogram paroxysmal θ characterizes cataplexy in mice and children. |
| Q33685660 | Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients |
| Q35967388 | Emerging drugs for narcolepsy |
| Q36691779 | Entrainment of temperature and activity rhythms to restricted feeding in orexin knock out mice |
| Q34092956 | Environmental toxins and risk of narcolepsy among people with HLA DQB1*0602. |
| Q34413665 | Etiopathogenesis and neurobiology of narcolepsy: a review |
| Q40519647 | Evaluation of polygenic risks for narcolepsy and essential hypersomnia |
| Q34770974 | Evidence for an association between migraine and the hypocretin receptor 1 gene |
| Q38891973 | Evidence for cognitive resource imbalance in adolescents with narcolepsy |
| Q30485748 | Evidence for metabolic hypothalamo-amygdala dysfunction in narcolepsy |
| Q27345325 | Evolutionarily conserved regulation of hypocretin neuron specification by Lhx9 |
| Q38540086 | Excessive daytime sleepiness in patients with ADHD--diagnostic and management strategies |
| Q52731375 | Excitation of Cortical nNOS/NK1R Neurons by Hypocretin 1 is Independent of Sleep Homeostasis. |
| Q44336714 | Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism |
| Q80391931 | Exclusive postsynaptic action of hypocretin-orexin on sublayer 6b cortical neurons |
| Q37738902 | Expert opinion on pharmacotherapy of narcolepsy |
| Q30402238 | Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy |
| Q84965563 | Expression and localization of the orexin-1 receptor (OX1R) after traumatic brain injury in mice |
| Q48252113 | Expression and role of receptor 1 for orexins in seminiferous tubules of rat testis. |
| Q47610304 | Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. |
| Q53115107 | Expression of orexin A and its receptor 1 in the epididymis of the South American camelid alpaca (Vicugna pacos). |
| Q34248978 | Expression patterns of corticotropin-releasing factor, arginine vasopressin, histidine decarboxylase, melanin-concentrating hormone, and orexin genes in the human hypothalamus. |
| Q43855637 | Facial expression recognition and emotional regulation in narcolepsy with cataplexy. |
| Q38814589 | Facilitation of contextual fear extinction by orexin-1 receptor antagonism is associated with the activation of specific amygdala cell subpopulations. |
| Q47902976 | Facing emotions in narcolepsy with cataplexy: haemodynamic and behavioural responses during emotional stimulation |
| Q30490183 | Feeding-elicited cataplexy in orexin knockout mice. |
| Q48680835 | Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities |
| Q48709003 | Forty winks: molecular basis of sleep disorders |
| Q32062017 | Fos expression in orexin neurons varies with behavioral state. |
| Q44606130 | From Club Drug to Orphan Drug: Sodium Oxybate (Xyrem) for the Treatment of Cataplexy |
| Q33646440 | From caveman companion to medical innovator: genomic insights into the origin and evolution of domestic dogs |
| Q41842113 | From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. |
| Q30835846 | Functional magnetic resonance imaging in narcolepsy and the kleine-levin syndrome |
| Q36854447 | Functional wiring of hypocretin and LC-NE neurons: implications for arousal |
| Q34990730 | Functions of the orexinergic/hypocretinergic system |
| Q48328326 | Furthering the understanding of the pathophysiology of narcolepsy |
| Q34502401 | G protein-coupled receptors: dominant players in cell-cell communication |
| Q39140728 | GABA Cells in the Central Nucleus of the Amygdala Promote Cataplexy. |
| Q42067265 | GABA Receptors on Orexin and Melanin-Concentrating Hormone Neurons Are Differentially Homeostatically Regulated Following Sleep Deprivation. |
| Q48504270 | GABA(B) receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus. |
| Q45197349 | GABA-mediated control of hypocretin- but not melanin-concentrating hormone-immunoreactive neurones during sleep in rats |
| Q33575159 | GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy |
| Q38943132 | GABAergic Neurons of the Central Amygdala Promote Cataplexy. |
| Q41887670 | GABAergic neurons in the preoptic area send direct inhibitory projections to orexin neurons |
| Q30496043 | GABAergic neurons intermingled with orexin and MCH neurons in the lateral hypothalamus discharge maximally during sleep |
| Q33787690 | GABAergic regulation of the perifornical-lateral hypothalamic neurons during non-rapid eye movement sleep in rats |
| Q46209377 | Gender differences between hypocretin/orexin knockout and wild type mice: age, body weight, body composition, metabolic markers, leptin and insulin resistance |
| Q36299545 | Generalized arousal of mammalian central nervous system |
| Q46276103 | Generation and Characterization of Functional Human Hypothalamic Neurons. |
| Q35075797 | Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells |
| Q34474283 | Genes for normal sleep and sleep disorders |
| Q30361534 | Genetic Analysis of Histamine Signaling in Larval Zebrafish Sleep. |
| Q48223052 | Genetic ablation of hypocretin neurons alters behavioral state transitions in zebrafish. |
| Q48691942 | Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity |
| Q37219884 | Genetic and environmental contributions to sleep-wake behavior in 12-year-old twins |
| Q37409494 | Genetic aspects of cluster headache |
| Q34333298 | Genetic association, seasonal infections and autoimmune basis of narcolepsy |
| Q37953793 | Genetic contributions to behavioural diversity at the gene-environment interface |
| Q34435156 | Genetics and genomics in neuropsychopharmacology: the impact on drug discovery and development |
| Q60916876 | Genetics of narcolepsy |
| Q39217292 | Genome-wide analysis of CNV (copy number variation) and their associations with narcolepsy in a Japanese population |
| Q36675167 | Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank |
| Q34545632 | Genome-wide association studies of sleep disorders |
| Q48344918 | Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy |
| Q47397164 | Genome-wide gene expression profiling of human narcolepsy. |
| Q42035451 | Genomewide association analysis of human narcolepsy and a new resistance gene |
| Q52875050 | Glucagon regulates orexin A secretion in humans and rodents. |
| Q45061870 | Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. |
| Q33708776 | Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. |
| Q46384657 | Greatly increased numbers of histamine cells in human narcolepsy with cataplexy |
| Q34308787 | Group III metabotropic glutamate receptors maintain tonic inhibition of excitatory synaptic input to hypocretin/orexin neurons. |
| Q37501097 | Growing Up with Type 1 Narcolepsy: Its Anthropometric and Endocrine Features |
| Q90624339 | Growth Hormone Deficiency and Excessive Sleepiness: A Case Report and Review of the Literature |
| Q27317087 | H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice |
| Q42913561 | HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency |
| Q48026022 | HLA dosage effect in narcolepsy with cataplexy |
| Q90437844 | HLA high-resolution typing by next-generation sequencing in Pandemrix-induced narcolepsy |
| Q30370632 | HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy |
| Q37220187 | HLA-DQB1 allele and hypocretin in Korean narcoleptics with cataplexy |
| Q61444179 | HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy |
| Q38233014 | Headache and sleep: shared pathophysiological mechanisms. |
| Q40315760 | High bicarbonate levels in narcoleptic children |
| Q35591448 | Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level |
| Q36170845 | Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency |
| Q45107957 | Histamine innervation and activation of septohippocampal GABAergic neurones: involvement of local ACh release |
| Q42006862 | Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states |
| Q36981092 | Histamine-HisCl1 receptor axis regulates wake-promoting signals in Drosophila melanogaster |
| Q30362536 | History of narcolepsy at Stanford University. |
| Q24644409 | History of the development of sleep medicine in the United States |
| Q38865497 | Hubs and spokes of the lateral hypothalamus: cell types, circuits and behaviour. |
| Q24606302 | Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction |
| Q42363420 | Human hypocretin-deficient narcolepsy - aberrant food choice due to impaired taste? |
| Q88068341 | Humanity’s Best Friend: A Dog-Centric Approach to Addressing Global Challenges |
| Q35236645 | Hypersomnia |
| Q34628648 | Hypersomnia and depressive symptoms: methodological and clinical aspects |
| Q38366488 | Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy |
| Q43996794 | Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus |
| Q48180671 | Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice |
| Q48864091 | Hypocretin (orexin) input to trigeminal and hypoglossal motoneurons in the cat: a double-labeling immunohistochemical study |
| Q39648815 | Hypocretin (orexin) regulates glutamate input to fast-spiking interneurons in layer V of the Fr2 region of the murine prefrontal cortex |
| Q38191600 | Hypocretin (orexin) regulation of sleep-to-wake transitions |
| Q34137170 | Hypocretin and GABA interact in the pontine reticular formation to increase wakefulness |
| Q36513244 | Hypocretin and human African trypanosomiasis |
| Q34155661 | Hypocretin and its emerging role as a target for treatment of sleep disorders |
| Q45289637 | Hypocretin and melanin-concentrating hormone in patients with Huntington disease |
| Q55442317 | Hypocretin as a Hub for Arousal and Motivation. |
| Q41785536 | Hypocretin deficiency develops during onset of human narcolepsy with cataplexy |
| Q44115086 | Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. |
| Q48606461 | Hypocretin is an early member of the incretin gene family |
| Q37738130 | Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights |
| Q36479367 | Hypocretin neuron-specific transcriptome profiling identifies the sleep modulator Kcnh4a |
| Q36891142 | Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy |
| Q46373122 | Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement |
| Q40726270 | Hypocretin stimulates [(35)S]GTP gamma S binding in Hcrtr 2-transfected cell lines and in brain homogenate |
| Q45300640 | Hypocretin-1 (orexin A) levels are normal in Huntington's disease |
| Q36951865 | Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis |
| Q37082095 | Hypocretin-1 and secondary signs in Huntington's disease |
| Q34277180 | Hypocretin-1 causes G protein activation and increases ACh release in rat pons. |
| Q28345076 | Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat |
| Q33485239 | Hypocretin-2 saporin lesions of the ventrolateral periaquaductal gray (vlPAG) increase REM sleep in hypocretin knockout mice |
| Q40781477 | Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. |
| Q37290211 | Hypocretin/Orexin Peptides Alter Spike Encoding by Serotonergic Dorsal Raphe Neurons through Two Distinct Mechanisms That Increase the Late Afterhyperpolarization |
| Q37618039 | Hypocretin/Orexin Peptides Excite Rat Neuroendocrine Dopamine Neurons through Orexin 2 Receptor-Mediated Activation of a Mixed Cation Current |
| Q39183160 | Hypocretin/Orexin and Plastic Adaptations Associated with Drug Abuse |
| Q44258622 | Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system |
| Q37299612 | Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis |
| Q33814590 | Hypocretin/orexin and narcolepsy: new basic and clinical insights |
| Q30482268 | Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. |
| Q37596060 | Hypocretin/orexin in arousal and stress |
| Q44835118 | Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. |
| Q38013859 | Hypocretin/orexin involvement in reward and reinforcement |
| Q34593415 | Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. |
| Q44785480 | Hypocretin/orexin peptide signaling in the ascending arousal system: elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentum |
| Q35948120 | Hypocretin/orexin prevents recovery from sickness |
| Q42510167 | Hypocretin/orexin suppresses corticotroph responsiveness in vitro |
| Q28187653 | Hypocretin/orexin, sleep and narcolepsy |
| Q33817194 | Hypocretin1/OrexinA-containing axons innervate locus coeruleus neurons that project to the Rat medial prefrontal cortex. Implication in the sleep-wakefulness cycle and cortical activation |
| Q34203591 | Hypocretin1/orexinA-immunoreactive axons form few synaptic contacts on rat ventral tegmental area neurons that project to the medial prefrontal cortex |
| Q36487999 | Hypocretinergic and non-hypocretinergic projections from the hypothalamus to the REM sleep executive area of the pons |
| Q44451302 | Hypocretinergic facilitation of synaptic activity of neurons in the nucleus pontis oralis of the cat. |
| Q103028780 | Hypocretinergic interactions with the serotonergic system regulate REM sleep and cataplexy |
| Q36260008 | Hypocretins (orexins) and sleep-wake disorders |
| Q42527611 | Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. |
| Q38027689 | Hypocretins and the neurobiology of sleep-wake mechanisms |
| Q37738128 | Hypocretins in the control of sleep and wakefulness. |
| Q34492938 | Hypothalamic and vagal neuropeptide circuitries regulating food intake |
| Q48455813 | Hypothalamic gray matter changes in narcoleptic patients |
| Q46564697 | Hypothalamic hypocretinergic/orexinergic neurons projecting to the oral pontine rapid eye movement sleep inducing site in the cat. |
| Q34741986 | Hypothalamic obesity in humans: what do we know and what can be done? |
| Q30311232 | Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2. |
| Q38353773 | Hypothalamic orexin neurons regulate arousal according to energy balance in mice |
| Q37284057 | Hypothalamic orexins/hypocretins as regulators of breathing |
| Q29619151 | Hypothalamic regulation of sleep and circadian rhythms |
| Q33401580 | IGFBP3 colocalizes with and regulates hypocretin (orexin) |
| Q37500060 | Identifying essential cell types and circuits in autism spectrum disorders. |
| Q48624631 | Immunogenetics and sleep disorders |
| Q30984327 | Immunohistochemical evidence for synaptic release of glutamate from orexin terminals in the locus coeruleus |
| Q38156224 | Immunology of stiff person syndrome and other GAD-associated neurological disorders |
| Q45987709 | Impact of obesity in children with narcolepsy. |
| Q91361810 | In vivo clonal expansion and phenotypes of hypocretin-specific CD4+ T cells in narcolepsy patients and controls |
| Q36992168 | Inactivation of median preoptic nucleus causes c-Fos expression in hypocretin- and serotonin-containing neurons in anesthetized rat |
| Q48156966 | Increase of histaminergic tuberomammillary neurons in narcolepsy |
| Q48614095 | Increased body mass index (BMI) in male narcoleptic patients, but not in HLA-DR2-positive healthy male volunteers |
| Q34475721 | Increased daytime sleepiness in patients with childhood craniopharyngioma and hypothalamic tumor involvement: review of the literature and perspectives. |
| Q44558376 | Increased frequency of migraine in narcoleptic patients: a confirmatory study |
| Q33725437 | Increased immune complexes of hypocretin autoantibodies in narcolepsy |
| Q30371742 | Increased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. |
| Q48460311 | Increasing length of wakefulness and modulation of hypocretin-1 in the wake-consolidated squirrel monkey |
| Q93022778 | Independent Component Analysis and Graph Theoretical Analysis in Patients with Narcolepsy |
| Q45949041 | Induction of active (REM) sleep and motor inhibition by hypocretin in the nucleus pontis oralis of the cat. |
| Q37081709 | Influence of inhibitory serotonergic inputs to orexin/hypocretin neurons on the diurnal rhythm of sleep and wakefulness |
| Q89448495 | Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist |
| Q42441383 | Inhibition of rostral basal forebrain neurons promotes wakefulness and induces FOS in orexin neurons |
| Q36718073 | Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins |
| Q34442421 | Integrating modern concepts of insomnia and its contemporary treatment into primary care |
| Q34109854 | Integration of human sleep-wake regulation and circadian rhythmicity |
| Q43878306 | Interaction of the hypocretins with neurotransmitters in the nucleus accumbens |
| Q38534913 | Interactions of the histamine and hypocretin systems in CNS disorders. |
| Q38284819 | Interactions of the orexin/hypocretin neurones and the histaminergic system |
| Q64052682 | Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjögren’s syndrome |
| Q37139316 | Interspecies genetics of eating disorder traits |
| Q46498301 | Intrathecal baclofen associated with improvement of consciousness disorders in spasticity patients |
| Q58560764 | Intravenous Immunoglobulin Therapy Administered Early after Narcolepsy Type 1 Onset in Three Patients Evaluated by Clinical and Polysomnographic Follow-Up |
| Q44355556 | Intravenously administered hypocretin-1 alters brain amino acid release: an in vivo microdialysis study in rats |
| Q34528172 | Invited review: genetic dissection of sleep |
| Q43878309 | Involvement of the serotonergic system in orexin-induced behavioral alterations in rats |
| Q40900071 | Is suvorexant a better choice than alternative hypnotics? |
| Q36700601 | K+ channels stimulated by glucose: a new energy-sensing pathway |
| Q37700398 | Lack of hypocretin attenuates behavioral changes produced by glutamatergic activation of the perifornical-lateral hypothalamic area |
| Q35152159 | Lateral hypothalamic neuropeptides in reward and drug addiction |
| Q35875205 | Lateral hypothalamic orexin/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference |
| Q39563714 | Lateral hypothalamus: early developmental expression and response to hypocretin (orexin). |
| Q34611455 | Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy |
| Q47949108 | Locomotor activity and the expression of orexin A and orexin B in aged female rhesus macaques |
| Q44859255 | Locomotor-dependent and -independent components to hypocretin-1 (orexin A) regulation in sleep-wake consolidating monkeys |
| Q37405078 | Loss of hypocretin (orexin) neurons with traumatic brain injury |
| Q48683622 | Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy |
| Q48687870 | MAO-A and COMT polymorphisms and gene effects in narcolepsy |
| Q36430136 | MHC class II proteins and disease: a structural perspective |
| Q34259192 | Mapping of the mRNAs for the hypocretin/orexin and melanin-concentrating hormone receptors: networks of overlapping peptide systems. |
| Q38558199 | Mapping the Hypocretin/Orexin Neuronal System: An Unexpectedly Productive Journey |
| Q44283284 | Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background |
| Q30386292 | Mechanistic insights into influenza vaccine-associated narcolepsy. |
| Q46576608 | Medications for the treatment of narcolepsy |
| Q28365028 | Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus |
| Q30486271 | Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle |
| Q34822618 | Melanin-concentrating hormone: a new sleep factor? |
| Q26770483 | Metabolic signals in sleep regulation: recent insights |
| Q36346477 | Metabolic state signalling through central hypocretin/orexin neurons. |
| Q55664351 | Microstructural Changes in Patients With Parkinson's Disease Comorbid With REM Sleep Behaviour Disorder and Depressive Symptoms. |
| Q40203695 | Mitigation of murine focal cerebral ischemia by the hypocretin/orexin system is associated with reduced inflammation |
| Q37999096 | Models for narcolepsy with cataplexy drug discovery |
| Q48805520 | Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: a microdialysis study |
| Q48704998 | Modulation of the promoter region of prepro-hypocretin by alpha-interferon |
| Q92376769 | Molecular codes and in vitro generation of hypocretin and melanin concentrating hormone neurons |
| Q36497536 | Molecular genetics and treatment of narcolepsy |
| Q41903543 | Monitoring the Right Collection: The Central Cholinergic Neurons as an Instructive Example |
| Q47772626 | Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway |
| Q33948588 | Monozygotic twins incompletely concordant for narcolepsy |
| Q46017271 | Month of birth is not a risk factor for narcolepsy with cataplexy in the Netherlands. |
| Q44426279 | Morphological study of orexin neurons in the hypothalamus of the Long–Evans rat, with special reference to co-expression of orexin and NADPH-diaphorase or nitric oxide synthase activities |
| Q26779153 | Moving from capstones toward cornerstones: successes and challenges in applying systems biology to identify mechanisms of autism spectrum disorders |
| Q44338120 | Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system. |
| Q46424846 | Muscarinic-2 and orexin-2 receptors on GABAergic and other neurons in the rat mesopontine tegmentum and their potential role in sleep-wake state control |
| Q46399561 | Muscle Activity During Sleep in Human Subjects, Rats, and Mice: Towards Translational Models of REM Sleep Without Atonia |
| Q48622072 | Muscle tone facilitation and inhibition after orexin-a (hypocretin-1) microinjections into the medial medulla |
| Q36301666 | Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy |
| Q33194998 | NMR Conformational Studies of Micelle-Bound Orexin-B: A Neuropeptide Involved in the Sleep/Awake Cycle and Feeding Regulation |
| Q56627695 | Narcolepsy |
| Q92035817 | Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment |
| Q57094544 | Narcolepsy Associated with Pandemrix Vaccine |
| Q36255408 | Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells. |
| Q41995022 | Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. |
| Q37807703 | Narcolepsy and cataplexy |
| Q60932913 | Narcolepsy and emotional experience: a review of the literature |
| Q33981657 | Narcolepsy and excessive daytime sleepiness |
| Q42370355 | Narcolepsy and influenza vaccination-the inappropriate awakening of immunity |
| Q33351116 | Narcolepsy and orexins: an example of progress in sleep research |
| Q33587566 | Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort |
| Q34296069 | Narcolepsy and the HLA region |
| Q47720695 | Narcolepsy and the T-cell receptor |
| Q36600966 | Narcolepsy and the hypocretin system--where motion meets emotion |
| Q30582000 | Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation |
| Q30362783 | Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. |
| Q30359247 | Narcolepsy as an immune-mediated disease |
| Q36744152 | Narcolepsy in African Americans |
| Q35107716 | Narcolepsy in the older adult: epidemiology, diagnosis and management |
| Q48113682 | Narcolepsy is a common phenotype in HSAN IE and ADCA-DN. |
| Q24649513 | Narcolepsy is strongly associated with the T-cell receptor alpha locus |
| Q34144175 | Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns |
| Q47094264 | Narcolepsy susceptibility gene CCR3 modulates sleep-wake patterns in mice. |
| Q36733271 | Narcolepsy with cataplexy |
| Q48500623 | Narcolepsy with cataplexy in early childhood |
| Q38195524 | Narcolepsy with cataplexy: diagnostic challenge in children |
| Q45246927 | Narcolepsy, from Westphal to hypocretin |
| Q48232721 | Narcolepsy, idiopathic hypersomnolence and related conditions |
| Q36606370 | Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity |
| Q47869008 | Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT. |
| Q38211898 | Narcolepsy: a clinical review |
| Q34072315 | Narcolepsy: a neurodegenerative disease of the hypocretin system? |
| Q35212990 | Narcolepsy: a review |
| Q36364195 | Narcolepsy: a review of evidence for autoimmune diathesis |
| Q34843237 | Narcolepsy: current treatment options and future approaches |
| Q35075673 | Narcolepsy: differential diagnosis or etiology in some cases of bipolar disorder and schizophrenia? |
| Q37091394 | Narcolepsy: immunological aspects |
| Q34691643 | Narcolepsy: let the patient's voice awaken us! |
| Q27004322 | Narcolepsy: neural mechanisms of sleepiness and cataplexy |
| Q32049276 | Narcolepsy: new understanding of irresistible sleep |
| Q42419076 | Narcoleptic orexin receptor knockout mice express enhanced cholinergic properties in laterodorsal tegmental neurons |
| Q51740583 | Neural Damage in Experimental Trypanosoma brucei gambiense Infection: Hypothalamic Peptidergic Sleep and Wake-Regulatory Neurons. |
| Q46750593 | Neural correlates of arousal-induced circadian clock resetting: hypocretin/orexin and the intergeniculate leaflet |
| Q59755770 | Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy |
| Q29615343 | Neural substrates of awakening probed with optogenetic control of hypocretin neurons |
| Q37807663 | Neurobiology of waking and sleeping |
| Q35791191 | Neurodegenerative disorders associated with diabetes mellitus |
| Q38049844 | Neuromodulation of brain states |
| Q46865807 | Neuronal Mechanisms for Sleep/Wake Regulation and Modulatory Drive |
| Q34571598 | Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. |
| Q38477044 | Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology |
| Q39207789 | Neuronal substrates for initiation, maintenance, and structural organization of sleep/wake states |
| Q28085477 | Neurons containing orexin or melanin concentrating hormone reciprocally regulate wake and sleep |
| Q34356717 | Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system. |
| Q35600016 | Neuropeptide gene polymorphisms and human behavioural disorders |
| Q36675494 | Neuropeptides as possible targets in sleep disorders |
| Q35952741 | Neuropeptides in hypothalamic neuronal disorders |
| Q35183957 | Neuropeptides: opportunities for drug discovery |
| Q34518670 | Neuropharmacology of Sleep and Wakefulness |
| Q36393701 | Neuropharmacology of Sleep and Wakefulness: 2012 Update |
| Q24658243 | Neurophysiology of sleep and wakefulness: basic science and clinical implications |
| Q48140316 | Neuropsychological findings in childhood narcolepsy |
| Q48711734 | Neuroscience. The sandman's secrets |
| Q47751740 | New Neuroscience Tools That Are Identifying the Sleep-Wake Circuit |
| Q27686789 | New approaches for the study of orexin function |
| Q37709565 | New approaches for the treatment of sleep disorders |
| Q34878785 | New developments in sleep research: molecular genetics, gene expression, and systems neurobiology |
| Q26851338 | New technologies for integrating genomic, environmental and trait data |
| Q36000839 | No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination |
| Q28480931 | Non-dipping blood pressure profile in narcolepsy with cataplexy |
| Q44871025 | Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models |
| Q42124350 | Normal Morning Melanin-Concentrating Hormone Levels and No Association with Rapid Eye Movement or Non-Rapid Eye Movement Sleep Parameters in Narcolepsy Type 1 and Type 2. |
| Q48434049 | Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis |
| Q47259221 | Not asleep, not quite awake |
| Q35011921 | Novel therapies for narcolepsy |
| Q26865384 | OX1 and OX2 orexin/hypocretin receptor pharmacogenetics |
| Q46417496 | Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). |
| Q90636795 | Optical probing of orexin/hypocretin receptor antagonists |
| Q38642277 | Optogenetic Investigation of Arousal Circuits |
| Q33623396 | Optogenetic deconstruction of sleep-wake circuitry in the brain |
| Q30485386 | Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice |
| Q38077489 | Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status |
| Q41957445 | Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy |
| Q54963732 | Orexin A Differentially Influences the Extinction Retention of Recent and Remote Fear Memory. |
| Q34559586 | Orexin A activates hypoglossal motoneurons and enhances genioglossus muscle activity in rats. |
| Q37576044 | Orexin A and orexin receptor 1 axonal traffic in dorsal roots at the CNS/PNS interface |
| Q45233267 | Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. |
| Q30377394 | Orexin Neurons Respond Differentially to Auditory Cues Associated with Appetitive versus Aversive Outcomes. |
| Q39026714 | Orexin OX2 Receptor Antagonists as Sleep Aids |
| Q59201264 | Orexin Receptor Antagonists |
| Q44349574 | Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. |
| Q33742356 | Orexin System: The Key for a Healthy Life |
| Q48465332 | Orexin excites rat inferior vestibular nuclear neurons via co-activation of OX1 and OX 2 receptors |
| Q36980393 | Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. |
| Q36665322 | Orexin gene transfer into the amygdala suppresses both spontaneous and emotion-induced cataplexy in orexin-knockout mice |
| Q36790716 | Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice |
| Q90260823 | Orexin in Respiratory and Autonomic Regulation, Health and Diseases |
| Q34050036 | Orexin mediates initiation of sexual behavior in sexually naive male rats, but is not critical for sexual performance. |
| Q24654773 | Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell |
| Q34696872 | Orexin neuronal circuitry: role in the regulation of sleep and wakefulness |
| Q34513315 | Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner |
| Q37332460 | Orexin neurons are necessary for the circadian control of REM sleep. |
| Q30558348 | Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice |
| Q36018973 | Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. |
| Q39603334 | Orexin receptor antagonism: an ascending multiple-dose study with almorexant. |
| Q38269308 | Orexin receptor antagonists--a patent review (2010 to August 2014). |
| Q37764786 | Orexin receptor antagonists: a new concept in CNS disorders? |
| Q37697791 | Orexin receptor antagonists: a review of promising compounds patented since 2006. |
| Q43889435 | Orexin receptor-1 (OX-R1) immunoreactivity in chemically identified neurons of the hypothalamus: focus on orexin targets involved in control of food and water intake |
| Q47982827 | Orexin receptor-1 in the locus coeruleus plays an important role in cue-dependent fear memory consolidation. |
| Q24597418 | Orexin receptors: pharmacology and therapeutic opportunities |
| Q33717450 | Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action |
| Q47718610 | Orexin research: patent news from 2016. |
| Q33770861 | Orexin signaling via the orexin 1 receptor mediates operant responding for food reinforcement. |
| Q36880278 | Orexin, stress, and anxiety/panic states |
| Q48239014 | Orexin-A expression in human peripheral tissues |
| Q37387709 | Orexin-A inputs onto visuomotor cell groups in the monkey brainstem |
| Q78482568 | Orexin-mediated feeding behavior involves both leptin-sensitive and -insensitive pathways |
| Q47699370 | Orexin/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain |
| Q43805360 | Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. |
| Q33643534 | Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention |
| Q39416935 | Orexins and the cardiovascular events of awakening |
| Q92537514 | Orexins/Hypocretins: Key Regulators of Energy Homeostasis |
| Q42513781 | Orexins/hypocretins excite basal forebrain cholinergic neurones |
| Q42696475 | Orexins: looking forward to sleep, back at addiction |
| Q47994268 | Organization of the histaminergic system in adult zebrafish (Danio rerio) brain: neuron number, location, and cotransmitters |
| Q37028758 | Orphan GPCR research |
| Q84979056 | Pathophysiology of cluster headache and other trigeminal autonomic cephalalgias |
| Q47927503 | Peptides that regulate food intake: regional, metabolic, and circadian specificity of lateral hypothalamic orexin A feeding stimulation |
| Q48459072 | Periodic leg movements during sleep and wakefulness in narcolepsy |
| Q95840633 | Perspective on the Multiple Pathways to Changing Brain States |
| Q36730631 | Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. |
| Q35040879 | Pharmacogenomics in the treatment of narcolepsy |
| Q91973279 | Pharmacological Characteristics of Porcine Orexin 2 Receptor and Mutants |
| Q35952470 | Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression |
| Q35548163 | Pharmacological management of narcolepsy |
| Q28287690 | Pharmacotherapy options for cataplexy |
| Q46265368 | Physiological functions of glucose-inhibited neurones. |
| Q43735442 | Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection |
| Q26822470 | Physiology of the orexinergic/hypocretinergic system: a revisit in 2012 |
| Q48185192 | Physiology. The perfect hypnotic? |
| Q44441275 | Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial |
| Q48670319 | Plasma orexin-A is lower in patients with narcolepsy |
| Q48629354 | Plasma orexin-A-like immunoreactivity in patients with sleep apnea hypopnea syndrome |
| Q48635419 | Polymorphisms of the tumor necrosis factor receptors: no association with narcolepsy in German patients |
| Q47860962 | Posterior hypothalamic modulation of ocular-responsive trigeminal subnucleus caudalis neurons is mediated by Orexin-A and Orexin1 receptors |
| Q43266688 | Potentiation of a functional autoantibody in narcolepsy by a cholinesterase inhibitor. |
| Q92690906 | Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation |
| Q32065449 | Prepro-orexin mRNA levels in the rat hypothalamus, and orexin receptors mRNA levels in the rat hypothalamus and adrenal gland are not influenced by the thyroid status. |
| Q34821484 | Presentations of primary hypersomnia in Chinese children |
| Q36836807 | Prevalence of eating disorders and eating attacks in narcolepsy |
| Q34628298 | Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist |
| Q34607196 | Promotion of sleep by targeting the orexin system in rats, dogs and humans |
| Q49961724 | Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling |
| Q34068000 | Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate |
| Q53139157 | Psychosocial and intellectual functioning in childhood narcolepsy. |
| Q44917818 | Pulsatile LH release is diminished, whereas FSH secretion is normal, in hypocretin-deficient narcoleptic men. |
| Q36564528 | QRFP and Its Receptors Regulate Locomotor Activity and Sleep in Zebrafish. |
| Q45128130 | Quality of life in children with narcolepsy. |
| Q35995496 | REM sleep characteristics in narcolepsy and REM sleep behavior disorder |
| Q37863871 | REM sleep: a biological and psychological paradox |
| Q37200112 | Rapid changes in glutamate levels in the posterior hypothalamus across sleep-wake states in freely behaving rats |
| Q48321095 | Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency |
| Q46304849 | Recovery from Coma Post-Cardiac Arrest Is Dependent on the Orexin Pathway. |
| Q64966255 | Reduced Plasma Orexin-A Concentrations are Associated with Cognitive Deficits in Anorexia Nervosa. |
| Q33285540 | Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain |
| Q43832867 | Reduction of daytime sleepiness in a depressive patient during adjunct treatment with modafinil |
| Q35586604 | Refinement of behavioural traits in animals for the genetic dissection of eating disorders |
| Q46965172 | Regulation by orexin of feeding behaviour and locomotor activity in the goldfish |
| Q46773011 | Regulation of hypocretin (orexin) expression in embryonic zebrafish |
| Q44368217 | Regulation of orexin neurons by the monoaminergic and cholinergic systems. |
| Q26822482 | Regulation of zebrafish sleep and arousal states: current and prospective approaches |
| Q48602913 | Relationship between CSF hypocretin levels and hypocretin neuronal loss |
| Q42523162 | Release of hypocretin (orexin) during waking and sleep states. |
| Q36553108 | Repeated injections of orexin-A developed behavioral tolerance to its analgesic effects in rats |
| Q35509945 | Respiration and autonomic regulation and orexin |
| Q48317017 | Respiratory regulation in narcolepsy |
| Q80973005 | Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy |
| Q35110705 | Response variability in Attention-Deficit/Hyperactivity Disorder: a neuronal and glial energetics hypothesis |
| Q48149724 | Restoration: potential for compensatory changes in numbers of neurons in adult human brain |
| Q36868678 | Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy. |
| Q35042283 | Reward-seeking behavior in human narcolepsy |
| Q39264695 | Rewiring brain circuits to block cataplexy in murine models of narcolepsy |
| Q34245006 | Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior |
| Q94561328 | Role of Brown Adipose Tissue in Adiposity Associated With Narcolepsy Type 1 |
| Q37440794 | Role of adenosine A(1) receptor in the perifornical-lateral hypothalamic area in sleep-wake regulation in rats |
| Q36270726 | Role of lateral hypothalamus in two aspects of attention in associative learning. |
| Q36774914 | Role of orexin in modulating arousal, feeding, and motivation |
| Q47371999 | Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders. |
| Q34989372 | Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy |
| Q37023183 | Role of the medial prefrontal cortex in cataplexy. |
| Q39026723 | Roles for Orexin/Hypocretin in the Control of Energy Balance and Metabolism |
| Q35573219 | Roles of orexins in the regulation of feeding and arousal |
| Q40243643 | Running promotes wakefulness and increases cataplexy in orexin knockout mice |
| Q42706199 | Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial |
| Q40596148 | Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy |
| Q48585000 | Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA. |
| Q44132550 | Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons. |
| Q43878301 | Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro. |
| Q44158613 | Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons |
| Q37132728 | Selective loss of GABA(B) receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. |
| Q34340556 | Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. |
| Q43100830 | Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity |
| Q48542310 | Sexually dimorphic expression of prepro-orexin mRNA in the rat hypothalamus |
| Q36256296 | Shared genetic risk factors for obstructive sleep apnea and obesity. |
| Q37167156 | Shining light on wakefulness and arousal. |
| Q39684347 | Similar changes of hypothalamic feeding-regulating peptides mRNAs and plasma leptin levels in PTHrP-, LIF-secreting tumors-induced cachectic rats and adjuvant arthritic rats. |
| Q37667235 | Sleep Disorders: Is the Trigemino-Cardiac Reflex a Missing Link? |
| Q84538458 | Sleep and headache |
| Q91856650 | Sleep and neurological autoimmune diseases |
| Q34451399 | Sleep disorders, obesity, and aging: the role of orexin |
| Q35236639 | Sleep disturbances, psychiatric disorders, and psychotropic drugs |
| Q43107033 | Sleep dynamics beyond traditional sleep macrostructure |
| Q64889988 | Sleep homeostasis and the circadian clock: Do the circadian pacemaker and the sleep homeostat influence each other’s functioning?☆. |
| Q37897942 | Sleep neurobiology from a clinical perspective |
| Q37139539 | Sleep problems in children with neurological disorders |
| Q34500449 | Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice. |
| Q37822544 | Sleep state switching |
| Q36980414 | Sleep transitions in hypocretin-deficient narcolepsy |
| Q57817996 | Sleep-Wake Cycling and Energy Conservation: Role of Hypocretin and the Lateral Hypothalamus in Dynamic State-Dependent Resource Optimization |
| Q39193471 | Sleep-Wake Disturbances After Traumatic Brain Injury: Synthesis of Human and Animal Studies. |
| Q48673197 | Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area |
| Q48473912 | Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy |
| Q35682954 | Sleep: a functional enigma |
| Q37999433 | Sleepiness that cannot be overcome: narcolepsy and cataplexy |
| Q48643470 | Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events |
| Q43130890 | Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice |
| Q42005677 | Spontaneous reporting of suspected narcolepsy after vaccination against pandemic influenza A (H1N1) in Germany |
| Q34443676 | Suvorexant for the treatment of insomnia |
| Q31113697 | Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials |
| Q42723113 | Synaptic interactions between perifornical lateral hypothalamic area, locus coeruleus nucleus and the oral pontine reticular nucleus are implicated in the stage succession during sleep-wakefulness cycle |
| Q45941348 | Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats. |
| Q34730569 | Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. |
| Q38096025 | Systems level immune response analysis and personalized medicine |
| Q59069335 | T cells in patients with narcolepsy target self-antigens of hypocretin neurons |
| Q35783354 | TCRA, P2RY11, and CPT1B/CHKB associations in Chinese narcolepsy |
| Q48624856 | TNFA promoter polymorphisms and narcolepsy |
| Q47747609 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. |
| Q38546959 | The Brain Correlates of Laugh and Cataplexy in Childhood Narcolepsy. |
| Q64264112 | The Effects of Amphetamine and Methamphetamine on the Release of Norepinephrine, Dopamine and Acetylcholine From the Brainstem Reticular Formation |
| Q36310854 | The G protein-coupled receptors: pharmacogenetics and disease |
| Q35006664 | The Geneva brain collection |
| Q39052250 | The Hypocretin/Orexin Neuronal Networks in Zebrafish |
| Q47819498 | The Molecular Basis of Insomnia: Implication for Therapeutic Approaches |
| Q34502802 | The Neurobiology of Sleep and Wakefulness |
| Q47772845 | The Neuropeptide Orexin-A Inhibits the GABAA Receptor by PKC and Ca2+/CaMKII-Dependent Phosphorylation of Its β1 Subunit. |
| Q55603146 | The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. |
| Q27325381 | The anatomical distribution of genetic associations. |
| Q47869796 | The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep |
| Q30431335 | The autoimmune basis of narcolepsy |
| Q33157223 | The borderland of epilepsy: clinical and molecular features of phenomena that mimic epileptic seizures |
| Q43644936 | The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats |
| Q47731938 | The cnm locus, a canine homologue of human autosomal forms of centronuclear myopathy, maps to chromosome 2. |
| Q36094392 | The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats |
| Q64275015 | The development of hypocretin deficiency in narcolepsy type 1 can be swift and closely linked to symptom onset: clues from a singular case |
| Q48238574 | The distinct movement disorder in anti-NMDA receptor encephalitis may be related to Status Dissociatus: a hypothesis |
| Q33947805 | The diurnal rhythm of hypocretin in young and old F344 rats |
| Q36375246 | The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors |
| Q34993019 | The genetic and molecular regulation of sleep: from fruit flies to humans |
| Q35172453 | The genetics of sleep disorders |
| Q38115678 | The histaminergic network in the brain: basic organization and role in disease |
| Q36550599 | The human hypothalamus in metabolic and episodic disorders. |
| Q38173326 | The hypocretin system and psychiatric disorders |
| Q36985867 | The hypocretin/orexin receptor: therapeutic prospective in sleep disorders |
| Q24537243 | The hypocretin/orexin system |
| Q35182252 | The hypocretin/orexin system in health and disease |
| Q34357064 | The hypocretin/orexin system mediates the extinction of fear memories. |
| Q38231949 | The hypocretin/orexin system: an increasingly important role in neuropsychiatry. |
| Q36923729 | The hypocretins and the reward function: what have we learned so far? |
| Q37338664 | The hypocretins as sensors for metabolism and arousal. |
| Q26830704 | The hypocretins/orexins: integrators of multiple physiological functions |
| Q34623823 | The hypocretins: setting the arousal threshold |
| Q35172398 | The hypothalamus in episodic brain disorders |
| Q37405862 | The impact of gender on timeliness of narcolepsy diagnosis |
| Q37072638 | The integrative role of orexin/hypocretin neurons in nociceptive perception and analgesic regulation. |
| Q47675384 | The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. |
| Q55921579 | The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes |
| Q34522821 | The mouse: genetics meets behaviour |
| Q48612846 | The narcoleptic borderland |
| Q48612827 | The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). |
| Q34575514 | The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness |
| Q90463916 | The neurobiological basis of narcolepsy |
| Q34770328 | The neurobiology of sleep: genetics, cellular physiology and subcortical networks |
| Q37802486 | The neurochemistry of awakening: findings from sleep disorder narcolepsy |
| Q46902600 | The orexin 1 receptor (HCRTR1) gene as a susceptibility gene contributing to polydipsia-hyponatremia in schizophrenia |
| Q34448938 | The orexin neuropeptide system: physical activity and hypothalamic function throughout the aging process. |
| Q35575085 | The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function |
| Q35027209 | The other side of the orexins: endocrine and metabolic actions |
| Q83380687 | The pathophysiologic basis of secondary narcolepsy and hypersomnia |
| Q27500366 | The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions |
| Q34792771 | The physiology and pharmacology of the orexins |
| Q43471042 | The prevalence of narcolepsy among Chinese in Hong Kong. |
| Q27014741 | The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin |
| Q35689733 | The role of chronobiology in sleep disorders medicine |
| Q35018717 | The role of hypocretin in driving arousal and goal-oriented behaviors. |
| Q26851982 | The role of orexin in post-stroke inflammation, cognitive decline, and depression |
| Q90627522 | The signal peptide as a new target for drug design |
| Q34446039 | The sleep switch: hypothalamic control of sleep and wakefulness |
| Q44357295 | The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarization. |
| Q46448184 | The wake-promoting hypocretin/orexin neurons change their response to noradrenaline after sleep deprivation. |
| Q45240196 | The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. |
| Q48017568 | Time- and state-dependent analysis of autonomic control in narcolepsy: higher heart rate with normal heart rate variability independent of sleep fragmentation |
| Q34439846 | Timing and consolidation of human sleep, wakefulness, and performance by a symphony of oscillators |
| Q34668388 | To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance |
| Q47787222 | Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics |
| Q24532097 | Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results |
| Q38828355 | Treatment Options for Narcolepsy |
| Q26771634 | Treatment paradigms for cataplexy in narcolepsy: past, present, and future |
| Q38533728 | Type 1 narcolepsy: a CD8(+) T cell-mediated disease? |
| Q36021334 | Understanding hereditary diseases using the dog and human as companion model systems |
| Q26795524 | Understanding how discrete populations of hypothalamic neurons orchestrate complicated behavioral states |
| Q28750452 | Unearthing the phylogenetic roots of sleep |
| Q90026112 | Update on narcolepsy |
| Q42262683 | Using magnetic resonance spectroscopy in narcolepsy to study the limbic mechanisms of cataplexy |
| Q33635419 | Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. |
| Q34013921 | Variant between CPT1B and CHKB associated with susceptibility to narcolepsy |
| Q36712995 | Vesicular glutamate (VGlut), GABA (VGAT), and acetylcholine (VACht) transporters in basal forebrain axon terminals innervating the lateral hypothalamus |
| Q42512060 | Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action |
| Q34395431 | Wakefulness: an eye-opening perspective on orexin neurons |
| Q30434168 | Why trypanosomes cause sleeping sickness. |
| Q92420144 | Widespread white matter connectivity abnormalities in narcolepsy type 1: A diffusion tensor imaging study |
| Q77727443 | [Narcolepsy and epidural obstetrical analgesia ] |
| Q79334194 | [Narcoleptic dogs. Significance for human narcolepsy] |
| Q51973350 | [Normal and disordered sleep] |
| Q51976629 | [The neurology of REM sleep. A synoptic tour de force]. |
| Q79935836 | [The neurotransmitter, hypocretin. An overview] |
Search more.